Cardio Diagnostics Holdings, Inc. SEC filings CDIOW
Cardio Diagnostics Holdings, Inc. has 295 filings in SEC EDGAR's recent list, going back to Jul 20, 2021. Its latest annual report, Form ARS, was filed on Jul 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 18, 2026 (shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 19, 2025 | — |
| EFFECT | Filing | Sep 9, 2025 | — |
| UPLOAD | Letter from the SEC | May 21, 2025 | — |
| CORRESP | Letter to the SEC | May 16, 2025 | — |
| UPLOAD | Letter from the SEC | May 7, 2025 | — |
| CORRESP | Letter to the SEC | May 7, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 24, 2025 | — |
| EFFECT | Filing | Feb 14, 2025 | — |
| CORRESP | Letter to the SEC | Feb 13, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 13, 2025 | — |
| EFFECT | Filing | Dec 3, 2024 | — |
| CORRESP | Letter to the SEC | Dec 2, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 26, 2024 | — |
| EFFECT | Filing | Sep 5, 2024 | — |
| D | Filing | Feb 6, 2024 | — |
| EFFECT | Filing | Feb 1, 2024 | — |
| CORRESP | Letter to the SEC | Jan 30, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 30, 2024 | — |
| DEL AM | Delaying amendment | Jan 29, 2024 | — |
| EFFECT | Filing | Apr 28, 2023 | — |
| EFFECT | Filing | Apr 11, 2023 | — |
| CORRESP | Letter to the SEC | Apr 10, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 10, 2023 | — |
| EFFECT | Filing | Jan 24, 2023 | — |
| CORRESP | Letter to the SEC | Jan 20, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 22, 2022 | — |
| 25-NSE | Delisting notice | Oct 26, 2022 | — |
| 425 | Filing | Oct 11, 2022 | — |
| SEC STAFF LETTER | Filing | Oct 7, 2022 | — |
| EFFECT | Filing | Oct 6, 2022 | — |
| CORRESP | Letter to the SEC | Oct 5, 2022 | — |
| CORRESP | Letter to the SEC | Oct 3, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 30, 2022 | — |
| 425 | Filing | Sep 23, 2022 | — |
| 425 | Filing | Sep 21, 2022 | — |
| CORRESP | Letter to the SEC | Sep 15, 2022 | — |
| 425 | Filing | Sep 15, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 9, 2022 | — |
| 425 | Filing | Aug 26, 2022 | — |
| 425 | Filing | Aug 25, 2022 | — |
| CORRESP | Letter to the SEC | Aug 23, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2022 | — |
| SEC STAFF LETTER | Filing | Aug 4, 2022 | — |
| AW | Form aw | Jul 27, 2022 | — |
| CORRESP | Letter to the SEC | Jul 25, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 5, 2022 | — |
| 425 | Filing | May 31, 2022 | — |
| EFFECT | Filing | Nov 22, 2021 | — |
| CERT | Filing | Nov 22, 2021 | — |
| 8-A12B | Form 8-a12b | Nov 22, 2021 | — |
| DRS | Filing | Jul 20, 2021 | — |
Showing 51 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- CDIO (Nasdaq), CDIOW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chicago, IL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1870144
- Former names
- Mana Capital Acquisition Corp. (until Oct 26, 2022)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.